Boot Hein J, Lukashov Vladimir V, van Remmerden Yvonne, Kimman Tjeerd G
Laboratory of Vaccine-preventable Diseases, National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA, Bilthoven, The Netherlands.
Virus Genes. 2007 Jan;34(1):75-85. doi: 10.1007/s11262-006-0012-9. Epub 2006 Sep 9.
Recombination between (human) enteroviruses is a common event in nature. Recently, it has been recognised that this feature has a major impact on the use of the live-attenuated polio vaccine during the end stage of polio eradication. The constraints for successful recombination between (vaccine-derived) polioviruses and human enteroviruses are, however, largely unknown. Here, we describe the identification and characterisation of a HEV-C field strain, isolated from the stool of a 2-year-old Dutch boy. Serotyping indicated that strain 89490 is a variant of strain CAV20a, which is already a variant of the prototype CAV20 strain. Amino acid sequence identity of 94.1% for the entire P1-region, and 92.4% for the major structural protein (VP1) indicates that this strain is indeed related to CAV20. However, virus neutralisation and Western blot analysis failed to show antigenic homology between the prototype CAV20 strain and our field strain. Furthermore, the 89490 field strain, just like the sub-prototype CAV20a, is able to replicate on RD-cells, while the prototype CAV20 and another sub-prototype CAV20b are not. On the basis of the phylogenetic analysis of the P2 and P3 region we expect that strain 89490 can act as recombination partner for the attenuated poliovirus strains of the Oral Polio Vaccine (OPV).
(人类)肠道病毒之间的重组在自然界中是常见事件。最近,人们认识到这一特性对脊髓灰质炎根除末期减毒活脊髓灰质炎疫苗的使用有重大影响。然而,(疫苗衍生的)脊髓灰质炎病毒与人类肠道病毒成功重组的限制因素在很大程度上尚不清楚。在此,我们描述了从一名2岁荷兰男孩粪便中分离出的一株戊型肝炎病毒C型野毒株的鉴定和特征。血清分型表明,89490株是CAV20a株的一个变种,而CAV20a株已经是原型CAV20株的一个变种。整个P1区域的氨基酸序列同一性为94.1%,主要结构蛋白(VP1)的氨基酸序列同一性为92.4%,这表明该毒株确实与CAV20有关。然而,病毒中和试验和蛋白质印迹分析未能显示原型CAV20株与我们的野毒株之间存在抗原同源性。此外,89490野毒株与亚原型CAV20a一样,能够在RD细胞上复制,而原型CAV20和另一个亚原型CAV20b则不能。基于对P2和P3区域的系统发育分析,我们预计89490株可作为口服脊髓灰质炎疫苗(OPV)减毒脊髓灰质炎病毒株的重组伙伴。